A new study from Johns Hopkins Kimmel Cancer Center suggests that disrupting fructose metabolism in tumor cells could enhance immune response against group 3 medulloblastoma, a highly aggressive pediatric brain cancer. Published in Acta Neuropathologica Communications, the research demonstrates that targeting how these cancer cells generate energy may slow disease progression and improve treatment outcomes.
Group 3 medulloblastoma is notoriously difficult to treat due to its tendency to metastasize and resist conventional therapies. The Johns Hopkins team focused on fructose metabolism, a pathway that tumor cells often exploit for energy. By blocking this process in mouse models, the researchers observed a significant reduction in tumor growth and an increase in immune cell infiltration. This suggests that metabolic interference can make tumors more vulnerable to the body's natural defenses.
The findings align with broader efforts in oncology to target metabolic vulnerabilities. For instance, companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are developing novel treatments for glioblastoma, another aggressive brain cancer. While CNS Pharmaceuticals focuses on DNA-damaging agents, the Johns Hopkins study highlights the potential of metabolic interventions in pediatric brain tumors.
According to the study, the blockade of fructose metabolism not only slowed tumor growth but also altered the tumor microenvironment, making it more conducive to immune attack. This dual effect—directly starving cancer cells while boosting immune response—could lead to combination therapies that improve survival rates for children with medulloblastoma.
Further research is needed to translate these findings into clinical applications. The Johns Hopkins team plans to explore specific inhibitors that can target fructose metabolism in humans, potentially in combination with existing immunotherapies. If successful, this approach could offer a new lifeline for patients with limited treatment options.
The study was supported by the Kimmel Cancer Center and published in Acta Neuropathologica Communications. For more details, the full paper is available through the journal's website.
